Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?

被引:26
作者
Khasraw, Mustafa [1 ]
Bell, David [1 ]
Wheeler, Helen [1 ]
机构
[1] Royal N Shore Hosp, Dept Med Oncol, St Leonards, NSW 2065, Australia
关键词
Temozolomide; Glioma; Glioblastoma multiforme; HIGH-GRADE GLIOMA;
D O I
10.1016/j.jocn.2008.09.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Temozolomide (TMZ) is an alkylating agent used in the management of gliomas. Although TMZ is generally safe and acute toxicity is well documented, there are limited data on long-term toxicities. We present three patients with glioma; all patients started on TMZ after having progressed following primary treatment. These patients have continued TMZ for 5 years, 7 years and 8 years respectively. So far they have had no serious side effects. We discuss these patients while raising the question of prolonged TMZ use. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:854 / 855
页数:2
相关论文
共 8 条
[1]
ARMSTRONG T, 2008, J CLIN ONCOL S, V26
[2]
COLMAN H, 2002, NEURO-ONCOLOGY, V4, P368
[3]
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma [J].
Hau, P. ;
Koch, D. ;
Hundsberger, T. ;
Marg, E. ;
Bauer, B. ;
Rudolph, R. ;
Rauch, M. ;
Brenner, A. ;
Rieckmann, P. ;
Schuth, J. ;
Jauch, T. ;
Koch, H. ;
Bogdahn, U. .
NEUROLOGY, 2007, 68 (09) :688-690
[4]
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature [J].
Noronha, Vanita ;
Berliner, Nancy ;
Ballen, Karen K. ;
Lacy, Jill ;
Kracher, Jean ;
Baehring, Joachim ;
Henson, John W. .
NEURO-ONCOLOGY, 2006, 8 (03) :280-283
[5]
PERRY J, 2008, J CLIN ONCOL S, V26
[6]
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment - case study and review of literature [J].
Singhal, Nimit ;
Selva-Nayagam, Sudarshan ;
Brown, Michael P. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (02) :229-230
[7]
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].
Stupp, R ;
Mason, WP ;
van den Bent, MJ ;
Weller, M ;
Fisher, B ;
Taphoorn, MJB ;
Belanger, K ;
Brandes, AA ;
Marosi, C ;
Bogdahn, U ;
Curschmann, J ;
Janzer, RC ;
Ludwin, SK ;
Gorlia, T ;
Allgeier, A ;
Lacombe, D ;
Cairncross, JG ;
Eisenhauer, E ;
Mirimanoff, RO ;
Van Den Weyngaert, D ;
Kaendler, S ;
Krauseneck, P ;
Vinolas, N ;
Villa, S ;
Wurm, RE ;
Maillot, MHB ;
Spagnolli, F ;
Kantor, G ;
Malhaire, JP ;
Renard, L ;
De Witte, O ;
Scandolaro, L ;
Vecht, CJ ;
Maingon, P ;
Lutterbach, J ;
Kobierska, A ;
Bolla, M ;
Souchon, R ;
Mitine, C ;
Tzuk-Shina, T ;
Kuten, A ;
Haferkamp, G ;
de Greve, J ;
Priou, F ;
Menten, J ;
Rutten, I ;
Clavere, P ;
Malmstrom, A ;
Jancar, B ;
Newlands, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :987-996
[8]
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma [J].
Su, YW ;
Chang, MC ;
Chiang, MF ;
Hsieh, RK .
JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (03) :315-318